Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YL201 + Toripalimab +/- Cisplatin in Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT07258979Phase 2Recruiting
- Sponsor
- MediLink Therapeutics
- Start
- Nov 2025
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 2, open-label trial of YL201 in nasopharyngeal carcinoma (NPC), sponsored by MediLink Therapeutics. Primary endpoints: Dose-limiting toxicities at 36 months, Treatment-emergent Adverse Events at 36 months and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
YL201
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07258979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07258979.